Adage Capital Partners
CYTK icon

Adage Capital Partners’s Cytokinetics CYTK Stock Holding History

Adage Capital Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-38,000
Closed -$2.09M – 933
2025
Q3 		$2.09M Buy
+38,000
New +$1.57M ﹤0.01% 803
2024
Q2 		– Sell
-37,500
Closed -$2.63M – 884
2024
Q1 		$2.63M Buy
37,500
+7,500
+25% +$580K 0.01% 760
2023
Q4 		$2.5M Buy
+30,000
New +$1.09M 0.01% 732
2021
Q3 		– Sell
-711,407
Closed -$14.1M – 1031
2021
Q2 		$14.1M Sell
711,407
-838,593
-54% -$19.7M 0.03% 588
2021
Q1 		$36.1M Buy
+1,550,000
New +$33.1M 0.07% 289

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners's CYTK Position: Q4 2025 in Review

Adage Capital Partners sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 38,000 shares — an estimated $2.09M sold.

Adage Capital Partners first reported a position in CYTK in Q1 2021 and held it in 5 quarters. The position peaked at $36.1M in Q1 2021. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Adage Capital Partners reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Adage Capital Partners sold 38,000 Cytokinetics shares in Q4 2025, an estimated $2.09M.
  • Adage Capital Partners first reported a position in Cytokinetics in Q1 2021 and held it in 5 quarters.
  • Adage Capital Partners's Cytokinetics position peaked at $36.1M in Q1 2021.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Adage Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.